Most Medicare drug plans cover Repatha (evolocumab). This includes stand-alone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Doctors prescribe ...

The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL)cholesterol under control with current ...

On the heels of highly anticipated cardiovascular outcomes data for PCSK9 med Repatha, Amgen has signed a money-back guarantee with Harvard Pilgrim. Through the first-of-its-kind contract, if a ...

Repatha is an effective medication that can lower LDL cholesterol and significantly reduce the risk of heart attacks and strokes. Like most drugs, Repatha can cause side effects. However long-term ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...

Most Medicare Part D plans include coverage for Repatha, though specific coverage details can vary among plans. Out-of-pocket costs for Repatha under Medicare Part D typically average around $49 per ...

Executives from Amgen (NASDAQ:AMGN) highlighted broad-based commercial growth, a set of six “key growth drivers,” and several late-stage pipeline programs during a conference session hosted by Leerink ...

Repatha is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Amgen has announced a price reduction for Repatha (evolocumab), bringing the list price of the therapy to $5,850 per year, ...

Amgen announced that all Repatha (evolocumab) devices are now available at a 60% reduced list price. This includes the pre-filled syringe, the SureClick autoinjector, and the Pushtronex device, an ...

A biotech drug used to treat inherited high cholesterol that last year saw its price reduced will soon only be available at that lower price. Thousand Oaks, California-based Amgen said Thursday that ...